Oxford Asset Management’s Haemonetics HAE Stock Holding History

Oxford Asset Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-17,557	Closed	-$2.01M	–	1899
2018 Q3	$2.01M	Sell	17,557 -24,831	-59%	-$2.57M	0.04%	662
2018 Q2	$3.81M	Buy	42,388 +22,943	+118%	+$1.94M	0.07%	301
2018 Q1	$1.42M	Sell	19,445 -20,321	-51%	-$1.39M	0.03%	760
2017 Q4	$2.32M	Buy	+39,766	New	+$2.09M	0.05%	496

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Oxford Asset Management's HAE Position: Q4 2018 in Review

Oxford Asset Management sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 17,557 shares — an estimated $2.01M sold.

Oxford Asset Management first reported a position in HAE in Q4 2017 and held it in 4 quarters. The position peaked at $3.81M in Q2 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

Oxford Asset Management reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
Oxford Asset Management sold 17,557 Haemonetics shares in Q4 2018, an estimated $2.01M.
Oxford Asset Management first reported a position in Haemonetics in Q4 2017 and held it in 4 quarters.
Oxford Asset Management's Haemonetics position peaked at $3.81M in Q2 2018.
279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Oxford Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.